The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
A direct‐acting antiviral (DAA)‐induced sustained virological response (SVR) reduces the risk of mortality. However, the risk factors associated with liver‐related and non‐liver‐related mortality following a SVR after DAA treatment are unclear. We assessed the incidence and risk factors of liver‐related and non‐liver‐related mortality in 1180 patients who achieved a SVR after DAA treatment. During...
Hepatocellular carcinoma (HCC) has high recurrence rates. HCC sometimes progresses from early‐stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage 0/A) to advanced‐stage HCC after repeated recurrences and treatments. HCC progression deteriorates quality of life and prognosis. However, the effect of direct‐acting antiviral (DAA)‐induced sustained virologic response (SVR) on HCC progression remains...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.